Clinical Studies: 2009 Start Date

Acne, Phase III
Sponsor: Stiefel, a GSK company
A Phase III, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
October 2009 to Present

Acne
Sponsor: Cipher Pharmaceuticals
A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
October 2009 to Present

Obesity
Sponsor: Eli Lilly and Company
A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women
October 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratoses on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025
August 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Actinic Keratoses on Non-head Locations
July 2009 to Present

Herpes Zoster
Sponsor: Inhibitex
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster
June 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of XXXX In Patients With Actinic Keratoses ON the Head (Face or Scalp)
June 2009 to Present

Actinic Keratoses
Sponsor: Peplin Operations
A Phase III Multi-center, Open-label Study to Evaluate the Safety and Efficacy of XXXX in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)
June 2009 to Present

Rosacea
Sponsor: Galderma
A Phase IV, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With XXXX When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea
June 2009 to November 2009

Psoriasis
Sponsor: Celgene Corporation
A Phase IIb, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of XXXX In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005
April 2009 to Present

Coronary Artery Disease
Sponsor: GlaxoSmithKline
A Phase III Randomized, Double Blind, Parallel Assignment, Clinical Outcomes Study of XXX Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events
February 2009 to Present

Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Novartis
A IIIb randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18 µg once daily vs open label tiotropium 18 µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease
February 2009 to Present

Psoriasis
Sponsor: Eli Lilly and Company
A Phase I, XXXXX (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris
January 2009 to Present

Clinical Studies